Eye disease: Roche chasing third indication for Vabysmo as it releases positive trial data 13-Feb-2023 By Jane Byrne Roche’s ophthalmic disease therapy, Vabysmo, has met its primary endpoint in two global Phase 3 trials.
EMA gives nod to pre-filled syringe form of Eylea 09-Apr-2020 By Ben Hargreaves Bayer announces that the product will be made available through ‘efficient and convenient’ drug delivery method in Europe.
Biogen expands ophthalmology portfolio with $310m biosimilar deal 07-Nov-2019 By Ben Hargreaves Biogen strikes deal with Samsung Bioepis for the commercial rights to two biosimilars referencing Lucentis and Eylea.
